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Abstract. It is estimated that >10,000 patients who undergo 
cystectomy for bladder cancer in the US each year receive a 
conventional ileal conduit and that >2,000 receive a continent 
urinary diversion. Case reports of primary intestinal adeno-
carcinomas in urinary conduits have been published recently, 
mainly in the urology literature. An epidemic of such cancers 
in this small, high-risk population seems to be emerging, 
particularly in conduits that utilize the colon. A case report and 
literature review was carried out. We describe a patient with a 
new primary adenocarcinoma arising in a colonic neobladder. 
We summarize prior literature describing intestinal adeno-
carcinomas that developed in an intestinal segment used for 
urinary diversion. Patients with urinary conduits of all types 
(particularly those utilizing colon rather than ileum) are at high 
risk of developing a second primary intestinal adenocarcinoma 
in the conduit. This population is likely to benefit from surveil-
lance measures aimed at detecting such cancers. The primary 
form of therapy remains adequate surgical resection. General 
surgeons should be aware of such patients as they may be 
involved in the diagnosis of, and surgery for, the cancer in the 
conduit.
Introduction
In 2008, the World Health Organization projected that cancer 
would become the leading cause of death in the world (1). 
Carcinoma of the urinary bladder is the ninth most commonly 
diagnosed type of cancer in the world (2). Over 70,000 people 
in the US develop this cancer every year (3) and the incidence 
is projected to increase (4). Comparable data are reported from 
other wealthy nations (5). In the US and most other countries, 
tobacco abuse is the main known environmental risk factor 
for the development of bladder cancer (6-8). The incidence in 
smokers is estimated to be two to three times as great as the 
incidence in non-smokers. In countries where S. haematobium 
is endemic, bladder infestation is the leading cause (2). In river 
basins draining the Himalayas (e.g., India, Pakistan, Myanmar, 
Vietnam), the groundwater contains high concentrations of 
arsenic, which is a major cause of bladder carcinoma (9). 
Additional known etiologic agents include exposure to certain 
aromatic amines such as those found in dyes and rubber, the 
chemotherapeutic agent cyclophosphamide, ionizing radiation, 
and various textiles and metals (7,10,11).
Colorectal carcinoma is the third most commonly diagnosed 
type of cancer in the world (1). Over 150,000 people in the US 
develop cancer of the colon or rectum every year (12). Adenomas 
arising in subjects without known polyposis syndromes are the 
most common precursor lesion. Hamartomas are also well-
described precursor lesions, as in Peutz-Jehgers syndrome. Other 
known causes of colorectal cancer include hereditary polyposis 
syndromes, Li-Fraumeni syndrome, inflammatory bowel 
disease, and ionizing radiation (13,14). Charred food and diets 
high in red meat and low in fiber, fruits and vegetables have been 
implicated as causative environmental agents (15-17). There is 
some evidence that a human colonic bacterium promotes colonic 
tumorigenesis (18). Tobacco abuse, including secondhand smoke 
exposure, is also associated with colorectal carcinoma develop-
ment (19), and the relationship appears to be dose-dependent (20).
Over 6,000 new cases of small intestinal cancer are diagnosed 
in the US annually (12). These include carcinoid, adenocarci-
noma, lymphoma, and sarcoma/gastrointestinal stromal tumor. 
Cancer of the small intestine accounts for about 1-2% of all 
gastrointestinal cancers. Predisposing causes include familial 
polyposis syndromes, Peutz-Jehgers syndrome, Crohn's disease, 
hereditary non-polyposis colon cancer syndromes, and cystic 
fibrosis (21). Because of the rarity of these cancers, the role of 
environmental agents such as tobacco-derived carcinogens has 
not been fully explored (22).
About 75% of bladder cancers are low-grade and non- 
muscle-invasive. They are usually managed by cystoscopic 
resection. Radical cystectomy is the mainstay of treatment 
for muscle-invasive carcinoma (though partial cystectomy is 
occasionally utilized). After radical cystectomy, some form of 
urinary diversion is required. Direct implantation of the ureters 
into non-isolated intestinal segments, particularly colon, was 
employed quite frequently after it was first described in 1852 
by Simon (23). Feris and Odel reported that patients with a 
uretero-sigmoidostomy often had intractable hyperchloremic 
metabolic acidosis and other metabolic complications so this 
procedure is now used infrequently (23). Uterosigmoidostomy 
was also found to lead to adenocarcinoma of the colon adjacent 
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to the location of ureteral implantation in an animal model (24). 
Austen and Kälble estimated that individuals between the ages 
of 25 and 30 with this form of diversion have a 477-fold increased 
lifetime risk of colon carcinoma and that patients between the 
ages of 55 and 60 years have an 8-fold increased lifetime risk 
(25).
Currently, urinary diversion into isolated bowel, typically 
ileum, is the most common method used after cystectomy 
(23,26). It was introduced by Bricker in the mid-twentieth 
century (27). Tizzoni and Foggi were the first to attempt creation 
of a neobladder in 1888 but the results were not satisfactory (23). 
During the 1970s, continent pouches were introduced again. 
In this procedure, a segment of bowel is isolated on a vascular 
pedicle, detubularized and reconfigured to create a spherical, 
low-pressure conduit. Ureters are implanted and the pouch is 
either connected to the native urethra (orthotopic neobladder) 
or a catheterizable stoma is created. Today, in young patients 
without major comorbid conditions, the orthotopic neobladder 
is the most commonly utilized form of urinary diversion and 
allows for a good quality of life (28,29).
The pattern of carcinogenesis in patients with urinary diver-
sions that maintain separation of urine and feces is different than 
that of patients with ureterosigmoidostomies. Cancers occurring 
after uterosigmoidostomy are almost all colon adenocarcinomas; 
those in isolated intestinal segments used for urinary diversion 
are usually adenocarcinomas but sarcomas and transitional 
cell, squamous cell, and oat cell carcinomas also occur occa-
sionally. The location of cancer developing in patients with 
ureterosigmoidostomy in practically always at the ureteroenteric 
anastomotic sites; those arising in isolated intestinal segments 
used for urinary diversion are located at the ureteroenteric anas-
tomotic sites in ~58% of instances and elsewhere in the conduit 
in the remaining 42% (25).
Despite the risk of metabolic and other complications, the 
use of intestinal segments for urinary diversion is generally pref-
erable to other options (cutaneous ureterostomy, percutaneous 
nephrostomy, or tissue-engineered bladder) (29). However, it is 
now also clear that patients with ileal conduits and continent 
diversions of various types (e.g., continent conduits and ortho-
topic neobladders) are at risk for second primary cancers. About 
13,000 individuals receive a cystectomy for bladder carcinoma in 
the US each year, and~17% undergo continent diversion (28,29). 
Based on these statistics, we estimate that about 11,000 patients 
receive an ileal conduit and >2,000 receive a neobladder each 
year in the US. In the US, the colon is used for the neobladder 
in about half of those who receive continent diversion; the 
small intestine is used for the other half. Considering that the 
neobladder procedure has been regularly used for the past 
twenty years, perhaps 10,000 people in the US currently have 
a neobladder. The typical latency period for developing cancer 
in an intestinal segment used for urinary diversion is about two 
decades. Because the mean survival duration for patients who 
have received curative-intent treatment for bladder carcinoma 
continues to increase, the risk of developing cancer in a urinary 
conduit for each patient is also increasing. It seems likely that 
an epidemic of such cancers, particularly in those who continue 
to smoke, is emerging at present. We sought to alert general 
surgeons about this phenomenon as they are likely to be asked 
to provide surgical care for such patients more frequently in the 
future.
Materials and methods
We recently encountered a patient who developed a new primary 
adenocarcinoma in an orthotopic neobladder created at the 
time of radical cystectomy for transitional cell carcinoma of the 
bladder 22 years earlier. Two separate literature searches were 
performed using PubMed on January 17, 2010. To evaluate the 
prior literature on this topic, one search mimicked that used by 
Austen et al (25). The search criteria were ‘urinary diversion’ and 
Figure 1. Photograph of the fresh specimen. The wooden pointer indicates the carcinoma (1 cm in diameter). It is adjacent to the lumen of the appendix (white 
arrow). There is a linear mucosal erosion (black arrow) caused by the blue ureteral stent.
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‘carcinoma’, using ‘case reports’ as a limitation. All languages 
were accepted. The second literature search, also using PubMed, 
was identical in all respects except that the search criteria were 
‘neobladder’ and ‘carcinoma’ with ‘case reports’ as a limitation.
Results
Case report. In 1987, a 48-year-old male was diagnosed with 
muscle-invasive transitional cell carcinoma of the urinary 
bladder. He had smoked 1.5 packs of cigarettes per day for 
many years. He underwent a cystoprostatectomy and had 
an ileocolonic neobladder constructed to provide continent 
urinary diversion. He continued to smoke cigarettes and in 2008 
he presented with symptomatic gallstone disease. Urology 
consultation was requested prior to cholecystectomy in order 
to determine whether further urologic procedures (revision of 
the neobladder, treatment of new primary urothelial tumors, 
etc.) might be indicated at the same operation. New-onset 
microscopic hematuria was detected and cystoscopy revealed 
two papillary tumors in the neobladder. One was invasive 
adenocarcinoma. Colonoscopy revealed no lesions in the 
colon remaining after the neobladder creation. He underwent 
open cholecystectomy, radical resection of the neobladder with 
regional lymphadenectomy, and implantation of ureters into a 
standard ileal conduit (Fig. 1). The operation was carried out 
by both surgeons and urologists. The prior radical cystectomy 
posed significant technical difficulties. Stents proved to be 
useful in avoiding damage to the ureters. Particular care was 
required to avoid injury to the obturator nerves, pelvic vessels, 
and the like, as much of the tissue overlying these structures 
had been resected at the time of the cystectomy. The pathology 
report indicated T1N0M0 colon adenocarcinoma. The second 
lesion seen at cystoscopy was an adenoma. The patient had no 
evidence of recurrence two years later.
There were 550 reports retrieved with our first computer-
generated literature search. Sixty-six described cases of tumor 
development in patients with isolated intestinal urinary diver-
sions created after cystectomy for bladder cancer (Fig. 2). There 
were 77 reports retrieved with the second search; 15 described 
cancers that developed in orthotopic neobladders (Fig. 3). Most 
were adenocarcinomas but transitional cell carcinoma, squa-
mous cell carcinoma, small cell undifferentiated carcinoma, and 
mesenchymal cancers such as lymphomas and sarcomas were 
also reported.
Discussion
It has been known for several decades that aromatic amine 
exposure in an occupational setting and tobacco abuse account 
for the majority of cases of bladder cancer in most areas of 
the world (30). As the exposure to carcinogens arising from 
industrial sources has been decreasing in the US, the propor-
tion of bladder cancers caused by tobacco abuse is increasing 
(31). Most experts conclude that the risk of cancer in isolated 
bowel segments used for urinary diversion after cystectomy is 
directly and causally related to the tobacco-derived urinary 
carcinogens bathing the epithelium, since most patients who 
abused tobacco before developing bladder carcinoma continue 
to smoke after cystectomy.
Since ureterosigmoidostomy is such a reliable model of 
colonic carcinogenesis, potential mechanisms have been inves-
tigated. One mechanism which could simultaneously explain 
tumor occurrence in both isolated and non-isolated gut segment 
urinary diversions involves inflammatory mediators (32). There 
are numerous reports implicating epidermal growth factor, 
various transforming growth factors and cytokines, and cyclo-
oxygenase-2 in the process of carcinogenesis, particularly in 
chronically inflamed tissues such as these urinary conduits (25).
Figure 2. Conventional ileal diversion. A segment of the intestine directs 
urine through a stoma into an external collecting bag. Cleveland Clinic: 
Treatment and Procedures. Urinary Reconstruction and Diversion. http://
my.clevelandclinic.org/services/urinary_reconstruction_and_diversion/hic_ 
urinary_reconstruction_and_diversion.aspx
Figure 3.  Neobladder. Intestine is made into a reservoir and connected to the 
urethra. Cleveland Clinic: Treatment and Procedures. Urinary Reconstruction 
and Diversion. http://my.clevelandclinic.org/services/urinary_reconstruction_ 
and_diversion/hic_urinary_reconstruction_and_diversion.aspx
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The causative role of tobacco abuse in carcinogenesis 
has been reviewed by Hecht (33). There are dozens of known 
carcinogens in cigarette smoke (34). They comprise various 
classes of agents and many are excreted in urine (35). Those 
agents believed to be most responsible for bladder carcinoma 
are 4-aminobiphenyl and other aromatic amines, although their 
relative potencies on a molar basis are not known. Whether 
tobacco-derived carcinogens are responsible for carcinoma of 
the small intestine is unknown at present since research on this 
topic is minimal (22). Hannan et al have provided a quantitative 
estimate of the risk of colorectal cancer in smokers (36). The 
relative importance of the various tobacco-derived carcinogens 
in carcinogenesis of the colon and rectum is uncertain. Many 
other ingested carcinogens derived from dietary sources are 
present in the colon. Resident bacterial, fungal, viral, and 
eukaryotic intestinal organisms, including protozoans (such 
as amoebas) and metazoans (such as tapeworms) produce an 
enormous number of metabolic products, most of which are not 
characterized. The causal relation between cigarette smoking 
and colorectal carcinogenesis has been well established recently 
(19,20). Tobacco-derived nitrosamines and heterocyclic amines 
are likely causative agents (33-39). The carcinogens responsible 
for carcinomas arising in intestinal segments used for urinary 
conduits are unknown but renal metabolism and urinary excre-
tion of tobacco-derived chemicals is an important route of 
elimination of these substances. Because 4-aminobiphenyl and 
other small aromatic amines are present in urine and appear 
to be the dominant known chemicals responsible for bladder 
cancer in tobacco abusers, they may be presumed to cause 
cancer in intestinal urinary conduits as well.
According to the Centers for Disease Control and Prevention, 
approximately 45 million Americans smoke cigarettes and are 
unable to quit (40). A person who continues to smoke after 
resection of his/her bladder cancer is at risk of developing a 
primary adenocarcinoma in the diverted bowel segment. The 
long-term exposure of bowel mucosa to tobacco-derived and 
non-tobacco-derived fecal carcinogens prior to the cystectomy, 
followed by exposure to urine containing different carcinogens 
derived from cigarette smoke, in addition to the proinflamma-
tory environment of the conduit, appears sufficient to explain 
the development of adenocarcinoma in patients with an ortho-
topic neobladder such as the patient described herein.
The risk of intestinal adenocarcinoma in a urinary conduit 
in patients with spina bifida or bladder exstrophy who receive a 
urinary diversion is appreciable (41). These patients presumably 
warrant periodic surveillance for this event, like patients after 
cystectomy for bladder carcinoma. The absolute risk of intestinal 
adenocarcinoma in a urinary conduit following cystectomy for 
bladder carcinoma is not known at present although there are 
many more such patients than spina bifida or bladder exstrophy 
patients. Sakano et al were apparently the first to report a patient 
who developed adenocarcinoma in an ileal conduit after cystec-
tomy for bladder carcinoma (42). Albertini et al were apparently 
the first to describe an adenocarcinoma arising in the colonic 
mucosa of a continent urinary reservoir following cystectomy 
for bladder cancer (43). Reports have usually been in the urology 
literature and occasionally in gynecology (44) and general 
surgery (45) studies. The literature prior to 2004 has been 
summarized by Austen and Kälbe (25). Our literature search 
yielded four case reports of intestinal adenocarcinoma arising in 
a urinary conduit created from an isolated segment of intestine 
since 2004 (46-49). It seems likely that the overall incidence of 
such second cancers is increasing.
In conclusion, as the results of treatment for bladder cancer 
are steadily improving, long-term survivors may develop other 
disorders requiring abdominal surgery, as in the case reported 
here. A general surgeon contemplating an elective abdominal 
operation for any reason in a patient who has had a prior cystec-
tomy for bladder carcinoma should be alert to the potential need 
for an additional procedure involving the urinary system. We 
believe that urological consultation and appropriate diagnostic 
tests should be obtained. Purely urological disorders (ureter-
enteric stricture, stones, etc.) may be discovered and warrant 
treatment at the same time. If an intestinal adenocarcinoma 
is found in the urinary conduit, resection may be curative. 
Collaboration between the general surgeon and the urologist can 
yield good results, as we have demonstrated.
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